Dyne Therapeutics, Inc. DYN

16.03 (0.48) (2.91%) as of 25 Sep
Market cap
$3.1B
P/E
0.0×
Insider Buys alert about insiders buying in the last 12 month
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Current Ratio
12.02 19.92 22.25 13.47

+8 more quarters

Net Debt/EBITDA
3.78 6.53 8.29 6.09
Debt/Assets
21.48% 14.41% 12.55% 11.43%
Debt/Equity
0.30 0.18 0.15 0.14
Asset Turnover
0.00 0.00 0.00 0.00
Operating CF/Net income
0.73 1.20 1.00 0.84
Capex/Depreciation
(4.63) (0.79) (3.64) (2.55)
Interest Coverage
0.00 0.00 0.00 0.00
Research and Development Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
0.00% 0.00% 0.00% 0.00%
Free Cash Flow per Share
(0.80) (0.88) (0.87) (0.64)
Cash per Share
5.43 5.89 8.65 5.58
Shareholders Equity per Share
4.24 5.24 7.57 4.88
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
4.24 5.24 7.57 4.88
Free Cash Flow
(131.80) (145.14) (112.32) (91.17)
Working Capital
859.86 969.78 1,075.96 746.41
Capital Expenditures
(1.51) (0.22) (0.48) (0.39)
Net Current Asset Value
646.03 806.13 911.76 630.99
Other line items
Quick Ratio
11.51 18.97 21.94 13.23
Revenue per Share
0.00 0.00 0.00 0.00
Operating CF per Share
(0.79) (0.88) (0.87) (0.64)
Capex per Share
(0.01) 0.00 0.00 0.00
Average Payables
13.08 8.90 7.32 9.11
Average Assets
861.50 900.51 939.10 817.95
Average Common Equity
636.80 767.01 800.98 698.66
Capex to Sales
0.00 0.00 0.00 0.00
Net Profit Margin
0.00% 0.00% 0.00% 0.00%

Fold the line items

Columns are period end dates